Your Checkup: Patient Education Health Podcast

The FDA just expanded Mounjaro’s label to include reducing the risk of major adverse cardiovascular events, and the headline is easy to love and easy to misunderstand. We slow it down and translate what the approval actually means for people living with type 2 diabetes, especially those worried about heart attack, stroke, and cardiovascular death.We unpack the exact endpoint behind the claim: MACE, which combines cardiovascular death, non-fatal heart attack, and non-fatal stroke, and we clarify what it is not saying (no, it is not “erasing plaque” or curing atherosclerotic cardiovascular disease). We also explain the real-world nuance around branding and indications: Mounjaro and Zepbound are both tirzepatide, but FDA labels are population-specific, and that can affect clinical decisions and insurance coverage.Then we walk through the Surpass-CVOT cardiovascular outcomes trial in plain English. The key twist is the comparator: tirzepatide was tested against Trulicity (dulaglutide), an active GLP-1 medication with known heart benefit, not placebo. That’s why understanding noninferiority vs superiority matters so much. We talk hazard ratios, absolute vs relative risk, and the surprising finding that bigger weight loss and a larger A1C drop did not translate into statistically superior cardiovascular outcomes during the study window.We close with practical guidance and a list of questions you can bring to your own checkup, including whether you have established cardiovascular disease, what makes you “high risk,” whether other cardioprotective meds are already doing the job, how dose changes could affect insulin or blood pressure meds, and what it will actually cost. If you found this helpful, subscribe, share the show with someone managing diabetes risk, and leave us a review so more people can find clear medical context.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

Your lab portal lights up red and suddenly you are doing mental math on a creatinine value you have never thought about before. We get it and we see it all the time in clinic, so we built a clear guide to the three kidney tests that confuse people most: creatinine, eGFR (estimated glomerular filtration rate), and urine albumin or protein in the urine.We start with what the kidneys actually do, down at the level of nephrons and glomeruli, then explain why creatinine is a helpful clue but not a perfect answer. Creatinine is measured, eGFR is estimated from that measurement plus factors like age and sex, and the two numbers typically move in opposite directions. From there, we tackle the big misconception: one low eGFR does not automatically mean chronic kidney disease. “Chronic” implies time, so we talk about why trends and prior labs matter, and how dehydration, acute illness, and certain medications can cause temporary changes that look scary on paper.Then we add the missing piece many people never hear about: urine albumin testing. Protein leakage can signal kidney damage even when filtration looks relatively preserved, which is especially important for people with diabetes and hypertension. We wrap by sharing the questions we run through as clinicians so you can bring the right context to your next checkup.Subscribe, share this with someone who reads labs at midnight, and please leave a quick review if it helps you feel more confident about your kidney numbers.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

A single executive order can spark a thousand headlines, but it can’t conjure new evidence into existence. We dig into the recent move to change childhood vaccine recommendations in the United States and why the American Academy of Pediatrics is pushing back with the same blunt message: the science hasn’t changed. If you’re a parent hearing “maybe the schedule isn’t safe,” we unpack what that claim would require scientifically and why politics is not a substitute for data.We also slow down on the parts that feel personal. Yes, it can look like “a lot of shots” when you’re staring at a baby’s thigh. But the number of syringes is not a measurement of immune overload. We talk through how the childhood immunization schedule is designed, what safety monitoring actually looks like, and why spacing vaccines out is not automatically safer. Delays create longer windows of vulnerability to measles, pertussis, and meningitis, and they add real burdens: more appointments, more missed work, more transportation stress, and more chances to fall behind.Then we address the question that never seems to die: vaccines and autism. We explain what happened, why researchers investigated it so intensely, and what the large studies across millions of children consistently show. From there, we land on the bigger takeaway: skepticism has two responsibilities, questioning what we think we know and accepting the answer when the evidence becomes overwhelming.If you want clear, evidence-based context from a family doctor and a nurse, hit play. Subscribe, share this with a parent who’s getting mixed messages, and leave a review so more people can find the show.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

Hi all, no new episode this week because we are on vacation! Feel free to enjoy any of our other episodes until next week :)Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

The words you use to describe your health can either pin you down or set you free. We talk about patient-first language and why a small change from “I am” to “I have” can ease shame, reduce stigma, and make room for real problem-solving in both chronic illness and mental health.We share how this shows up in everyday clinic conversations: diabetes versus “a diabetic,” obesity versus “an obese person,” and especially the tricky stuff like anxiety, depression, and bipolar disorder. When symptoms feel baked into your personality, it’s easy to say “I’m crazy” or “this is just me.” We walk through a reframing that helps you separate your identity from what you’re experiencing, so it becomes you versus the condition, not you as the condition. That distance can make next steps like therapy, coping skills, and medication feel less like a judgment and more like care.We also talk about how mental health can be misunderstood socially, how migraines and processing can collide with fast-paced conversation, and we keep things light with a weekend recap, comfort food, and a reality TV check-in. If you’ve ever struggled to explain what you’re feeling or felt defined by a diagnosis, this one is for you.Subscribe for more patient education conversations, share this with someone who needs a kinder way to talk about their mental health, and leave us a review with the words that have helped you most.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

We break down why Cyclospora spikes every summer in the United States and why contaminated fresh produce can cause days to weeks of watery diarrhea. We share what to watch for, what testing to request, and how to lower risk without swearing off fruits and vegetables.• what Cyclospora is and why humans are the only known host• why May through August is peak season due to oocyst maturation• which foods show up most in outbreaks like cilantro and bagged salad mixes• why routine washing and chlorine are not reliable against Cyclospora• how fecal oral spread works and why it is not typically person to person• signature symptoms including explosive watery diarrhea and waxing and waning illness• who is at higher risk for severe disease including immunocompromised patients• why routine stool tests can miss it and the need for specific Cyclospora testing• first-line treatment with TMP-SMX and practical hydration tips• prevention strategies including recalls, cooking produce, and travel precautionsLeave us a quick review. You could just give us a quick endorsement.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

That moment when you stare into your medicine cabinet and think, “How did I end up taking all of these?” is more common than people admit and it’s loaded with meaning. We talk through the hidden emotions behind prescriptions: fear, identity, shame, and the quiet belief that needing medication means you failed. From our seats in primary care and nursing, we offer a calmer, more practical way to look at it: medicines are tools, not trophies, and avoiding them isn’t a badge of honor either. We break medications into two clear buckets. Some help you feel better right now (pain relief, reflux meds, inhalers, allergy treatments). Others prevent future problems (statins, blood pressure medication, diabetes medication, osteoporosis meds) and the benefit can be almost invisible, which is exactly the point. We use the seatbelt analogy to explain why “not feeling different” can still mean a medication is working, and how to think in probabilities instead of scary absolutes. We also talk about side effects: what’s common, what’s rare, why many are reversible, and why it’s reasonable to ask for time to read and reflect before committing to a daily pill. Then we get into the messy realities: supplements with slick marketing, direct-to-consumer drug ads, influencers, and even credentialed voices making claims without evidence. We explain why polypharmacy (often five or more meds) can create dizziness, falls, confusion, and mystery symptoms, and why deprescribing can be one of the best things a primary care clinician does. We also draw a bright line around higher-risk tools like opioids and benzodiazepines, when short-term use makes sense, and why opioids and benzos should never be taken together. If you want a smarter, less anxious framework for your next medication conversation, hit play, then subscribe, share this with a friend who’s overwhelmed by their med list, and leave a review so more patients can find it.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

Sunlight feels harmless until you zoom in far enough to see what it’s doing inside a single skin cell. Today we follow that path, from UVA and UVB radiation to DNA damage, then through the built-in systems your body uses to prevent skin cancer in the first place. We keep it plainspoken but accurate, because understanding the biology makes the prevention advice feel a lot less like nagging and a lot more like control.We talk about melanin and why tanning is a defense response, not a health goal, plus the difference between DNA damage and a permanent mutation. Then we meet one of the most important safety players in the story: P53, the protein that can pause cell division for repairs or trigger apoptosis when a cell is too damaged to keep. We also explain why sunburn pain and peeling are signs of real cellular injury, not just a temporary cosmetic annoyance.From there, we compare basal cell carcinoma, squamous cell carcinoma, and melanoma, including why melanoma depth is such a big deal for spread and survival. We cover why most moles never become cancer, what changes are worth acting on, and how to use the ABCDE method and the ugly duckling sign. We also address a persistent myth directly: skin cancer can occur in every skin color, and it may show up in different places like palms, soles, and under nails.We’re Ed Delesky, a family medicine doctor, and Nicola Aruffo, a nurse, and we want you to leave with a practical plan: reduce future UV exposure, know what’s normal for your skin, and get help when something evolves. If this helped you, subscribe, share it with a friend who lives for “just one more hour in the sun,” and leave a review so more people can find the show.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

Cardio has been the default prescription for heart health for decades, but a growing body of evidence suggests we’ve been overlooking a major protective tool: strength training. We dig into a large, long-running research dataset that followed more than 117,000 women for nearly 15 years and found a powerful link between resistance training and lower heart attack risk. The number that stops people in their tracks: at least two hours of weekly strength training was associated with a dramatically lower risk of heart attack, with meaningful reductions in major cardiovascular events too.We also slow down and explain what those results do and don’t mean. Because the study is observational, it can’t prove that lifting weights directly prevents heart attacks. So we talk through why associations can still be useful, what “dose dependent” patterns add to the story, and how lifestyle factors like sleep, nutrition, and smoking can blur the picture. Then we connect the dots on plausible mechanisms, including better blood pressure control, improved insulin sensitivity, healthier body composition, less visceral fat, and protection against age-related muscle loss and declining function.If lifting feels intimidating, we make it practical. You don’t need to live in the gym or become a powerlifter to get benefits. We share an achievable weekly target (think 90 to 120 minutes), simple ways to start with dumbbells, resistance bands, machines, or bodyweight movements, and why pairing strength training with aerobic exercise may be the best overall approach for cardiovascular disease prevention.If this helped you rethink your workout plan, subscribe, share the episode with a friend, and leave a review so more people can find the show. What’s one strength move you could start this week?Study Citation:Zhang, T, Zhang, Y, Lee, D. et al. Resistance Training, Aerobic Activity, Television Viewing, and Risk of Major Cardiovascular Events in U.S. Women. JACC. null2026, 0 (0) .https://doi.org/10.1016/j.jacc.2026.04.036Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

We break down Medicare’s brand-new GLP-1 Bridge Program and explain why headlines are both true and incomplete. We lay out the real eligibility rules, the $50 copay promise, and the smarter questions to ask so you and your clinician can find the right coverage pathway. • why Medicare historically excludes weight loss medications and what changed with modern obesity medicine • what the GLP-1 Bridge Program is designed to do and why it is not universal coverage • the $50 copay detail and why office visits labs and deductibles can still affect total cost • who does not qualify because another Medicare Part D pathway may already apply • the three eligibility “doors” based on BMI and specific risk conditions • which GLP-1 medications are included at the time of recording and the planned program timeline • how to prepare for an appointment and the exact phrasing that helps your clinician pick the right route • why checking CMS and staying current matters as rules evolve You can send us an email, you can find us on Threads, follow us on Instagram, or leave us some fan mail.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

The hardest part about antidepressants is often not the pill, it is the question you ask yourself before you ever bring it up: “Is this serious enough?” We think that question keeps too many people stuck. We are Ed Delesky (family medicine doctor) and Nicole Aruffo (nurse), and we walk through a clearer test: is depression or anxiety affecting your ability to live your life the way you want to live it?We unpack the stigma that makes mental health feel different from every other medical problem, even though it lives in the brain like anything else. We use simple, patient-friendly analogies to explain how antidepressants work: a dimmer switch turned back up, or glasses that help you see more clearly. We also cover the practical signals we look for in primary care when deciding whether it is time to consider medication for depression or anxiety: symptoms lasting weeks to months, daily function taking a hit, sleep and motivation sliding, and foundational steps like therapy, movement, and sleep support not being enough on their own.We also demystify what starting an SSRI or SNRI can feel like, including why these medications usually take six to eight weeks to show real benefits and why a subtle improvement can still be life-changing. If you worry about dependence, personality changes, or taking something forever, we address those fears directly and talk about how many people use antidepressants for a season, not a lifetime. If this conversation helps, subscribe, share it with a friend, and leave a review so more people can find care that actually works.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

We break down migraines as a neurologic condition with a real brain-based chain reaction, not a character flaw or a one-off “bad headache.” We share practical prevention habits, how to track triggers, and how acute and preventive migraine medications fit together so you can walk into your next visit prepared. • what makes a migraine different from other headache types • common and less common migraine presentations including aura and scary look-alikes • the five-step migraine chain reaction including CGRP and pain amplification • high-yield triggers like stress, sleep changes, skipped meals, hormones, smells, and weather shifts • consistency as the core prevention theme across sleep, exercise, eating, and stress • migraine diary basics to identify patterns and improve your neurologist visit • when headaches warrant a call to a clinician and what red flags to take seriously • acute treatment options including OTC meds, triptans, CGRP blockers, and anti-nausea meds • medication overuse headache risk when acute meds are used too often • preventive options including beta blockers, anti-seizure meds, antidepressants, and Botox You can find us on Threads, you could send us an email, or you can send us some fan mail. We still have that voice-based fan mail still waiting for that first fateful one. Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

A headline like “weight loss drugs may reduce breast cancer risk” grabs attention fast, but the real story lives in the fine print. We take you through a new Penn Medicine study that observed lower breast cancer rates among women with overweight or obesity who used GLP-1 medications, then we translate what that finding actually means in plain language. Observational data can reveal a signal worth studying, but it cannot prove the medication caused the outcome, and that distinction matters for your decisions and your expectations. We also zoom out to the bigger why: obesity is not just about body size. Fat tissue is biologically active, shaping chronic inflammation, estrogen exposure after menopause, insulin resistance, and even how well the immune system spots abnormal cells. Those pathways help explain why obesity is linked to many cancers, including postmenopausal breast cancer, and why researchers are curious whether effective obesity treatment could shift risk over time. Then we get practical. We review what stronger evidence from randomized controlled trials says so far: GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound do not appear to increase breast cancer risk in the available trial data, even though most trials were not designed to study cancer outcomes for many years. We also discuss why newer studies seem most suggestive for hormone receptor positive breast cancer, along with the leading theories: weight loss itself, improved metabolic health and insulin signaling, reduced inflammation, and the still-unclear possibility of direct GLP-1 effects in cancer biology. If you like evidence-based medicine with real-world context (and a little Philly-life banter), subscribe, share this episode with a friend, and leave a review so more people can find the show. What question do you want answered next about GLP-1s, obesity treatment, or cancer risk?ReferencesRisk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-Analysis. Ko A, Chang YC, Bahar F, et al. Annals of Internal Medicine. 2025;. doi:10.7326/ANNALS-25-02237.Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-Analysis. Piccoli GF, Mesquita LA, Stein C, et al. The Journal of Clinical Endocrinology and Metabolism. 2021;106(3):912-921. doi:10.1210/clinem/dgaa891.Glucagon-Like Peptide 1 Receptor Agonists and Cancer Risk: The Good, the Bad and the Unknown. Mannucci E, Dicembrini I. Nature Reviews. Clinical Oncology. 2026;23(6):459-470. doi:10.1038/s41571-026-01135-0.GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women. McDonald ES, Gillis LB, Gabriel P, et al. JCO Oncology Practice. 2026;:101200OP2600485. doi:10.1200/OP-26-00485.GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: A real-world analysis.. Shah Z, Hundal J, Afridi S, et al. Journal of Clinical Oncology. 2026;44(Suppl 16):10548. doi:10.1200/JCO.2026.44.16_suppl.10548.Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer. Tatum KL, Dahman B, Stevenson A, et al. JAMA Network Open. 2026;9(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133.Association of Glucagon-Like Peptide-1 Receptor Agonists With Risk of Cancers-Evidence From a Drug Target Mendelian Randomization and Clinical Trials. Sun Y, Liu Y, Dian Y, et al. International Journal of Surgery (London, England). 2024;110(8):4688-4694. doi:10.1097/JS9.0000000000001514.GLP-1 receptor agonists and breast cancer risk in type 2 diabetes.. Guo Cheng and Amanda Ward. Journal of Clinical Oncology. 2025;43(Suppl 16):10557. doi:10.1200/JCO.2025.43.16_suppl.10557.Glucagon-Like Peptide-1 Analogues and Risk of Breast Cancer in Women With Type 2 Diabetes: Population Based Cohort Study Using the UK Clinical Practice Research Datalink. Hicks BM, Yin H, Yu OH, et al. BMJ (Clinical Research Ed.). 2016;355:i5340. doi:10.1136/bmj.i5340.GLP-1 Receptor Agonists and Cancer: Current Clinical Evidence and Translational Opportunities for Preclinical Research. Valencia-Rincón E, Rai R, Chandra V, Wellberg EA. The Journal of Clinical Investigation. 2025;135(21):e194743. doi:10.1172/JCI194743.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

That scary nutrition headline about preservatives and high blood pressure is everywhere right now and it’s easy to jump straight from “linked” to “proven.” We slow it down and do what we’d do in an exam room: look at what the study actually says, what it doesn’t say, and how to translate it into real-life choices that protect your heart without turning grocery shopping into a panic spiral.We talk through a new European Heart Journal paper using data from the NutriNet-Santé cohort (over 112,000 adults followed for nearly eight years) that finds several common food preservatives are associated with a higher risk of developing hypertension and cardiovascular disease. We explain why that word “associated” matters, how observational nutrition research can be confounded by overall ultra-processed food intake, sodium, fiber, lifestyle, and other factors, and why the results are best viewed as a signal not a verdict.Then we get practical by walking through a typical kitchen day and pointing out where you might run into additives like sodium nitrite, potassium sorbate, phosphoric acid, citric acid, and calcium propionate: breads, deli meats, chips, frozen meals, and even cola beverages. We also share the habits with the strongest evidence for blood pressure control: more minimally processed foods, more fruits and vegetables, less excess sodium, regular activity, better sleep, and stress management.If you found this helpful, subscribe, share it with a friend or neighbor, and leave a review so more people can find clear, patient-centered health info. What’s the first preservative you spot when you check five labels in your kitchen?Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

Breathing out shouldn’t feel like pushing air through a straw, but for millions of people that’s the daily reality of COPD. We sit down and translate chronic obstructive pulmonary disease into plain English, starting with what the name really means and why the main problem is often getting air out, not just getting air in. If you’ve ever heard someone say they “can’t catch their breath,” we give you a clear picture of what may be happening inside the lungs.We walk through a simple model of breathing using an upside-down tree and tiny balloon-like air sacs, then explain what changes in COPD: inflamed, narrowed airways and air sacs that lose their stretch. That combination can trap air, making each new breath feel harder than the last. We also talk about the slow burn of how COPD develops over time, why smoking is the most common cause, and how pollution, occupational dust or chemicals, secondhand smoke, and rare genetic factors can also play a role.From there, we get practical. We cover common COPD symptoms (shortness of breath with activity, chronic cough, mucus, wheezing, fatigue), how spirometry helps diagnose airflow limitation, and what treatment can actually do. We discuss inhalers, pulmonary rehabilitation, oxygen therapy for advanced cases, and why staying up to date on flu, RSV, and COVID vaccines matters for people at higher risk. We also break down COPD exacerbations, the flare-ups often triggered by infections that can cause a step down in lung function, and why early prevention and timely care are so important.Stick around for our post-medicine banter too. If this helped you understand your body a little better, subscribe, share it with someone who needs it, and leave a review so more people can find straightforward health education.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

Cortisol is getting blamed for basically everything online, and we get why it’s tempting: it gives a neat explanation for feeling tired, stressed, bloated, or “off.” But as a family medicine doctor and a nurse, we want to bring the conversation back to what cortisol actually does, what real testing looks like, and why most people don’t need to treat normal life stress like a hormonal crisis.From there, we zoom out to other trendy health topics we keep seeing everywhere: gut health and the microbiome, pricey supplement stacks, and the promise that one test will finally explain your symptoms. We talk about the evidence and the limits, plus the unglamorous basics that move the needle for most people: fiber, plants, sleep, exercise, and cutting back on ultra-processed foods.We also dig into CGMs and “glucose spikes,” including what’s normal (yes, exercise can raise glucose) and what actually signals risk, like blood sugar staying elevated after meals. Then we hit high-protein culture, why protein helps, why more isn’t always better, and how longevity trends can distract from what matters most. Our bottom line: wellness marketing moves faster than science, so we aim for practical, evidence-based choices you can stick with.If you found this helpful, subscribe, share it with a friend who’s stuck in health-trend overwhelm, and leave a review so more people can find the show.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

“Rare, deadly virus” is a phrase that can hijack your nervous system, especially after the last few years. We slow the whole story down and walk through what hantavirus is, why it’s trending again, and how to tell the difference between a serious public health investigation and a true pandemic threat.We start with the headline that pulled hantavirus back into the spotlight: an unusual outbreak tied to a cruise ship traveling through parts of South America, with multiple passengers becoming seriously ill and reported deaths. From there, we explain why experts are paying close attention to the Andes virus strain, the one hantavirus with evidence of possible person-to-person spread, and what that actually means in real life. The key nuance: even when human transmission happens, it appears to require close, prolonged contact, not the kind of casual exposure that drives rapid global spread.Then we zoom into the practical, everyday risks that matter most for listeners. Hantavirus pulmonary syndrome (HPS) can begin with flu-like symptoms such as fever, fatigue, muscle aches, headaches, and nausea, and in some cases it can progress quickly to severe lung problems. We cover the most common route of infection: rodent exposure, especially when cleaning dusty enclosed spaces like sheds, cabins, garages, barns, and attics. You’ll leave with clear prevention steps inspired by public health guidance, like ventilating first, using disinfectant, wearing gloves, and avoiding dry sweeping or vacuuming droppings.If you want facts, context, and a calmer way to process outbreak news, hit play, share this with someone who’s anxious about the headlines, and subscribe so you don’t miss the next checkup. If our show helps, leave a review and tell us what health topic you want us to unpack next.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

GLP-1 medications can feel like a Rorschach test online: one person calls Ozempic or Wegovy a miracle, another calls it miserable, and almost nobody explains what the “normal middle” looks like. We wanted to fix that with a practical walkthrough of what tends to happen after you start a GLP-1 receptor agonist, especially in those first weeks when you’re on a low dose and you’re wondering if anything is happening at all. We talk through the early ramp-up, realistic weight loss expectations, and the biggest lived experience change we hear from patients: food noise getting quieter. We break down the difference between normal hunger cues and constant appetite chatter, why cravings often drop, and how that creates a real window of opportunity to build routines that used to be hard. We also get honest about common side effects like nausea, constipation, and feeling overly full, plus simple strategies that can make them more manageable and safer. Then we zoom out to the long game: what it means to treat obesity as a chronic condition, why plateaus don’t automatically mean the medication “stopped working,” and how to define success beyond a single scale number using cardiometabolic health wins. After the clinical talk, we lighten things up with some banter about Ollie’s pet store obsession and the strange things strangers say on a walk. If this helped you, subscribe, share it with a loved one, and leave a review so more people can find practical, judgment-free education on GLP-1s and healthy weight loss.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski